We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
+22.79%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$359M
AUM Growth
+$110M
Cap. Flow
+$97.8M
Cap. Flow %
27.21%
Top 10 Hldgs %
61.96%
Holding
53
New
19
Increased
12
Reduced
12
Closed
9

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$20.1M
2
BBIO icon
BridgeBio Pharma
BBIO
+$20M
3
CYTK icon
Cytokinetics
CYTK
+$18.9M
4
GH icon
Guardant Health
GH
+$10.1M
5
KIDS icon
OrthoPediatrics
KIDS
+$9.04M

Top Sells

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$14.5M
2
QDEL icon
QuidelOrtho
QDEL
+$8.76M
3
PCRX icon
Pacira BioSciences
PCRX
+$5.04M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.68M
5
NUVB icon
Nuvation Bio
NUVB
+$3.46M

Sector Composition

Rank Sector Weight
1 Healthcare 96.72%
2 Industrials 3.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLAY icon
26
Relay Therapeutics
RLAY
$4.02B
$3.73M 1.04%
+450,000
New +$4.39M
COGT icon
27
Cogent Biosciences
COGT
$6.79B
$3.73M 1.04%
+555,500
New +$3.43M
OPCH icon
28
Option Care Health
OPCH
$3.4B
$3.35M 0.93%
100,000
-48,800
-33% -$1.58M
VKTX icon
29
Viking Therapeutics
VKTX
$4.04B
$3.2M 0.89%
+39,046
New +$1.74M
DXCM icon
30
DexCom
DXCM
$27.6B
$3.19M 0.89%
23,000
– –
BBSI icon
31
Barrett Business Services
BBSI
$976M
$3.04M 0.85%
96,000
+44,000
+85% +$1.28M
OVID icon
32
Ovid Therapeutics
OVID
$435M
$3M 0.83%
+983,200
New +$3.29M
PCRX icon
33
Pacira BioSciences
PCRX
$1.02B
$2.76M 0.77%
94,362
-164,062
-63% -$5.04M
ZBH icon
34
Zimmer Biomet
ZBH
$17.7B
$2.5M 0.69%
+18,908
New +$2.36M
MURA
35
DELISTED
Mural Oncology
MURA
$1.96M 0.54%
400,000
-18,505
-4% -$89.8K
LENZ
36
LENZ Therapeutics
LENZ
$172M
$1.45M 0.4%
65,000
-128,134
-66% -$2.66M
TXG icon
37
10x Genomics
TXG
$5.87B
$1.13M 0.31%
+30,000
New +$1.32M
BMEA icon
38
Biomea Fusion
BMEA
$90.4M
$1.12M 0.31%
75,000
+32,009
+74% +$527K
NUVB icon
39
Nuvation Bio
NUVB
$2.24B
$910K 0.25%
250,000
-1,800,000
-88% -$3.46M
PRVA icon
40
Privia Health
PRVA
$3.21B
$882K 0.25%
45,000
-87,158
-66% -$1.84M
KZR
41
DELISTED
Kezar Life Sciences
KZR
$869K 0.24%
96,360
-240,173
-71% -$2.19M
AGIO icon
42
Agios Pharmaceuticals
AGIO
$2.16B
$731K 0.2%
+25,000
New +$669K
TECX
43
Tectonic Therapeutic
TECX
$573M
$725K 0.2%
+47,210
New +$748K
ABSI icon
44
Absci
ABSI
$1.28B
$142K 0.04%
+25,000
New +$113K
DSGN icon
45
Design Therapeutics
DSGN
$736M
– –
-280,000
Closed -$742K
LKFT
46
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
– –
-120,000
Closed -$4.88M
ORIC icon
47
CALL
Oric Pharmaceuticals
ORIC
$1.25B
– –
-200,000
Closed -$1.84M
ORIC icon
48
Oric Pharmaceuticals
ORIC
$1.25B
– –
-1,578,263
Closed -$14.5M
PRTA icon
49
CALL
Prothena Corp
PRTA
$458M
– –
-53,500
Closed -$1.94M
QDEL icon
50
QuidelOrtho
QDEL
$1.09B
– –
-118,920
Closed -$8.76M
1
2
3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q1 2024 Portfolio in Review

As of Q1 2024, Prosight Management held 53 positions worth $359M, up 44% from $249M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Prosight Management deployed $97.8M of net new capital in Q1 2024, opening 19 new positions and adding to 12 existing holdings. Its largest new stake was Roivant Sciences: 1,860,000 shares worth $19.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Pacira BioSciences, an estimated $5.04M trimmed.

  • Prosight Management's largest Q1 2024 buy was Roivant Sciences: 1,860,000 shares worth $19.6M.
  • Prosight Management added most to OrthoPediatrics in Q1 2024, an estimated $9.04M increase.
  • Prosight Management's biggest Q1 2024 reduction was Pacira BioSciences, cutting an estimated $5.04M.
  • Prosight Management fully exited Oric Pharmaceuticals in Q1 2024, selling an estimated $14.5M.
  • Prosight Management's ten largest holdings make up 62% of its $359M portfolio in Q1 2024.
  • Prosight Management opened 19 new positions and closed 9 in Q1 2024.
  • Prosight Management's portfolio value rose 44% quarter-over-quarter to $359M.

Based on Prosight Management's 13F filing for Q1 2024, filed 15 May 2024.